Shots:

• The US FDA has issued a EUA for Evusheld to treat pre-exposure prophylaxis of COVID-19 in adults & adolescents aged ≥12yrs. with no adequate immune response to COVID-19 vaccination & whom COVID-19 vaccination is not recommended. The 1st dose is expected to be available shortly
• In P-III (PROVENT) trial, 77% reduction in primary analysis & 83% at a median of 6mos. over PBO & showed robust efficacy & long-term protection with 1 dose in a high-risk population. The EUA is based on the P-III (STORM CHASER) & P-I (Evusheld) trial
• Evusheld is a combination of 2 LAABs i.e., tixagevimab & cilgavimab which was derived from B-cells donated by convalescent patients after a SARS-CoV-2 virus

/ article | Ref: AstraZeneca | Image: Al Jazeera